-
Mashup Score: 0
Anitocabtagene autoleucel generated durable response in patients with relapsed/refractory multiple myeloma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0Iparomlimab/Tuvonralimab Plus Chemo ± Bevacizumab Yields Responses in Recurrent/Metastatic Cervical Cancer - 2 hour(s) ago
First-line paromlimab/tuvonralimab plus chemotherapy with or without bevacizumab was active in recurrent/metastatic cervical cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2
Katherine L. Nathanson, MD, discusses the identification of reversion mutations in BRCA1/2 in response to therapy among patients with breast cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
The addition of pembrolizumab to radiation did not improve survival in unresected, stage I or II non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on 5-year data for tremelimumab plus durvalumab in unresectable HCC.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 4
Panelists discuss the importance of molecular testing in NSCLC, particularly for ALK rearrangements, and explore how recent advancements and emerging technologies are shaping first-line treatment selection for ALK-positive patients.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3
First-line IMM-1-104 plus chemotherapy produced responses and disease control in patients with pancreatic cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0EMBARK on XTANDI - Advanced Prostate Cancer OncLive - 13 hour(s) ago
Sponsored by Astellas Pharma US, Inc. and Pfizer Inc. Neal Shore, MD, FACS GenesisCare US Myrtle Beach, South Carolina Stephen Freedland, MD Warschaw, Robertson, Law Families Chair in Prostate Cancer Professor of Urology Cedars-Sinai, Department of Urology Los Angeles, California The speakers have entered into a written agreement and have been compensated for their services in connection with this program. Review the prostate cancer disease state continuum, focusing on a specific subset of patients with
Categories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2FDA Grants Breakthrough Device Designation to DCISionRT for Breast Cancer With DCIS - 14 hour(s) ago
The FDA has granted a breakthrough device designation to the DCISionRT test for patients with breast cancer with ductal carcinoma in situ.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3
Health Canada approved fruquintinib for select patients with metastatic colorectal cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
Anitocabtagene autoleucel generated durable response in patients with relapsed/refractory multiple myeloma. @ASH_hematology #ASH24 #MMSM https://t.co/mKv7lig7mB